EP1242071A4 - Use of parthenolide to inhibit cancer - Google Patents

Use of parthenolide to inhibit cancer

Info

Publication number
EP1242071A4
EP1242071A4 EP00988155A EP00988155A EP1242071A4 EP 1242071 A4 EP1242071 A4 EP 1242071A4 EP 00988155 A EP00988155 A EP 00988155A EP 00988155 A EP00988155 A EP 00988155A EP 1242071 A4 EP1242071 A4 EP 1242071A4
Authority
EP
European Patent Office
Prior art keywords
parthenolide
inhibit cancer
cancer
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00988155A
Other languages
German (de)
French (fr)
Other versions
EP1242071A1 (en
Inventor
Harikrishna Nakshatri
Christopher J Sweeney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of EP1242071A1 publication Critical patent/EP1242071A1/en
Publication of EP1242071A4 publication Critical patent/EP1242071A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
EP00988155A 1999-12-23 2000-12-19 Use of parthenolide to inhibit cancer Withdrawn EP1242071A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17302399P 1999-12-23 1999-12-23
US17302499P 1999-12-23 1999-12-23
US173023P 1999-12-23
US173024P 1999-12-23
PCT/US2000/034469 WO2001045699A1 (en) 1999-12-23 2000-12-19 Use of parthenolide to inhibit cancer

Publications (2)

Publication Number Publication Date
EP1242071A1 EP1242071A1 (en) 2002-09-25
EP1242071A4 true EP1242071A4 (en) 2004-12-29

Family

ID=26868708

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00988155A Withdrawn EP1242071A4 (en) 1999-12-23 2000-12-19 Use of parthenolide to inhibit cancer

Country Status (4)

Country Link
EP (1) EP1242071A4 (en)
AU (2) AU780573B2 (en)
CA (1) CA2406733A1 (en)
WO (1) WO2001045699A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346251B1 (en) * 1999-06-15 2002-02-12 Mark Zamoyski Compositions and methods for treating psoriasis
US6355251B1 (en) * 1999-06-15 2002-03-12 Mark Zamoyski Compositions and methods for epidermal chemexfoliation
US20020058077A1 (en) * 2000-11-15 2002-05-16 National University Of Singapore Cancer chemotherapeutical and chemopreventive agent
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1496880A4 (en) * 2002-04-24 2007-12-12 Res Dev Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
US7192614B2 (en) 2002-11-05 2007-03-20 Gelstat Corporation Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
US20040086579A1 (en) * 2002-11-05 2004-05-06 Higgins James W. Dietary supplement comprising parthenolide
WO2004112819A1 (en) * 2003-06-13 2004-12-29 Gelstat Corporation Compositions and methods of treatment comprising plant extracts
ES2369083T3 (en) * 2003-07-11 2011-11-25 University Of Kentucky Research Foundation USE OF PARTENOLIDE DERIVATIVES AS ANTILEUCEMIC AND CYTOTOXIC AGENTS.
US7678904B2 (en) 2003-07-11 2010-03-16 University Of Kentucky Use of parthenolide derivatives as antileukemic and cytotoxic agents
WO2008007450A1 (en) * 2006-07-14 2008-01-17 Mmt Co., Ltd. Food, drink and medicinal composition having antitumor effect
WO2013071066A1 (en) * 2011-11-11 2013-05-16 The Broad Institute, Inc. Signatures associated with the response to cancer therapy
CN113136364B (en) * 2021-04-13 2022-05-03 广东唯泰生物科技有限公司 Preparation method and recovery method of decidua-muralis mesenchymal stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022774A2 (en) * 1995-01-26 1996-08-01 Ashbury Research Corporation Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins
WO1999033463A1 (en) * 1997-12-23 1999-07-08 Moser, René SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022774A2 (en) * 1995-01-26 1996-08-01 Ashbury Research Corporation Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins
WO1999033463A1 (en) * 1997-12-23 1999-07-08 Moser, René SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b)

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BALDWIN ET AL: "THE NF-kB AND IkB PROTEINS: New Discoveries and Insights", ANNUAL REVIEW OF IMMUNOLOGY, vol. 14, 1996, pages 649 - 683, XP002095262, ISSN: 0732-0582 *
HEHNER S P ET AL: "The Antiinflammatory Sesquiterpene Lactone Parthenolide Inhibits NF-kB by Targeting the IkB Kinase Complex", JOURNAL OF IMMUNOLOGY, vol. 163, no. 10, 1999, pages 5617 - 5623, XP002247261, ISSN: 0022-1767 *
IRUELA-ARISPE M L ET AL: "ANGIOGENESIS: A DYNAMIC BALANCE OF STIMULATORS AND INHIBITORS", THROMBOSIS AND HAEMOSTASIS, vol. 78, no. 1, 1997, pages 672 - 677, XP009004101, ISSN: 0340-6245 *
JAIN N K ET AL: "Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats", JOURNAL OF ETHNOPHARMACOLOGY, vol. 68, no. 1-3, 1999, pages 251 - 259, XP002278725, ISSN: 0378-8741 *
MONDRANONDRA I-O ET AL: "SESQUITERPENE LACTONES AND OTHER CONSTITUENTS FROM A CYTOTOXIC EXTRACT OF MICHELIA-FLORIBUNDA", PHARMACEUTICAL RESEARCH, vol. 7, no. 12, 1990, pages 1269 - 1272, XP009030203, ISSN: 0724-8741 *
PATEL NIKHIL M ET AL: "Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide", ONCOGENE, vol. 19, no. 36, 24 August 2000 (2000-08-24), pages 4159 - 4169, XP002278726, ISSN: 0950-9232 *
ROBLES M ET AL: "Recent studies on the zoopharmacognosy, pharmacology and neurotoxicology of sesquiterpene lactones", PLANTA MEDICA, vol. 61, no. 3, 1995, pages 199 - 203, XP009030206, ISSN: 0032-0943 *
SCHWARTZ S.A. ET AL: "The role of NF-kB/IkB proteins in cancer: implications for novel treatment strategies", SURGICAL ONCOLOGY, vol. 8, November 1999 (1999-11-01), pages 143 - 153, XP002475660 *
See also references of WO0145699A1 *
SHARMA H W ET AL: "THE NF-KAPPAB TRANSCRIPTION FACTOR IN ONCOGENESIS", ANTICANCER RESEARCH, vol. 16, March 1996 (1996-03-01), pages 589 - 596, XP002925508, ISSN: 0250-7005 *
YOSHIDA A ET AL: "Suppression of retinal neovascularization by the NF-[kappa]B inhibitor pyrrolidine dithiocarbamate in mice", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 40, no. 7, 1999, pages 1624 - 1629, XP009038300, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
AU2005202984B2 (en) 2009-01-08
CA2406733A1 (en) 2001-06-28
AU2005202984A1 (en) 2005-08-04
WO2001045699A1 (en) 2001-06-28
EP1242071A1 (en) 2002-09-25
AU2439201A (en) 2001-07-03
AU780573B2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
AU2001290936A1 (en) Application of water nanoclusters to skin
PL355101A1 (en) Use of h1
IL147748A0 (en) Use of etodolac to treat cancer
EP1242071A4 (en) Use of parthenolide to inhibit cancer
EG22530A (en) Preparation of substituted piperidin-4-ones
AU7104500A (en) Use of rafp to inhibit or prevent apoptosis
EP1225919A4 (en) Treatment of cancer
GB9923964D0 (en) Improvements to submarine ploughs
HUP0203900A3 (en) Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9923948D0 (en) Improvements to submarine ploughs
GB2353306B (en) Improvements to ploughs
GB2353304B (en) Improvements to ploughs
IL150477A0 (en) Novel therapeutic use of enoxaparin
GB0018053D0 (en) Improvements to ploughs
GB9915098D0 (en) Treatment of aluminium objects
HU1859U (en) Case to help provision of accident
GB9901904D0 (en) RTherapeutic use of human pheramones
TW411782U (en) Structure of adjustable convenient shoes
TW389030U (en) Improvement of waterproof structure of waterproof shoes
TW445775U (en) Improved structure of bra
TW494728U (en) Improved structure of bra
AU3738300A (en) Use of interleukin-11 to prevent immune-mediated cytotoxicity
GB9908537D0 (en) Improvements relating to cosmetics
TW394123U (en) Structure of emery-roller

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAKSHATRI, HARIKRISHNA

Inventor name: SWEENEY, CHRISTOPHER J.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 31/34 A

Ipc: 7A 61K 31/337 B

Ipc: 7A 61K 31/365 B

Ipc: 7A 61P 9/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20041110

17Q First examination report despatched

Effective date: 20070724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110701